Hangzhou, China

Qinjie Weng

This inventor holds 2 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignees: Chinese Academy of Sciences, Guangzhou Lixin Pharmaceutical Co., Ltd., Zhejiang University. Active years: 2019-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qinjie Weng. Retrieved from https://idiyas.com/inventor/qinjie-weng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 50.0

 

 

Average Co-Inventor Count = 8.2

ph-index = 1

Forward Citations = 1(Granted Patents)


Location History:

  • Zhejiang, CN (2019)
  • Hangzhou, CN (2022)

Company Filing History:


Years Active: 2019-2022

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Inventor Qinjie Weng

Introduction: Qinjie Weng is a prolific inventor based in Hangzhou, China, known for his groundbreaking contributions to various technological fields.

Latest Patents: Qinjie Weng holds several patents in the areas of artificial intelligence, renewable energy, and biotechnology, showcasing his diverse range of expertise.

Career Highlights: With a career spanning over two decades, Qinjie Weng has worked with leading research institutions and companies to develop innovative solutions that have had a significant impact on the industry.

Collaborations: Throughout his career, Qinjie Weng has collaborated with top scientists, engineers, and researchers from around the world, fostering a culture of innovation and knowledge sharing.

Conclusion: Qinjie Weng's dedication to pushing the boundaries of technology and his passion for creating solutions to complex challenges make him a standout figure in the world of inventors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…